# US 6,726,932 B2 · Fatty acid-containing composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,932 B2
- Document ID: US6726932B2
- Status: Granted
- Kind: B2
- Application number: 09/788,007
- Filed: 2001-02-16
- Published: 2003-01-23
- Granted: 2004-04-27
- Earliest claimed: 2000-02-18
- Assignees: Nippon Zoki Pharmaceutical Co., Ltd.
- Inventors: Jin-emon Konishi
- Web page: https://patentgrep.com/patent/US6726932B2

## CPC

- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a composition for enhancing the pharmacological activity of a water-soluble silicate polymer which comprises the water-soluble silicate polymer and a saturated fatty acid in pharmaceutically effective amounts for use as a medicine such as anti-allergic agent. The water soluble silicate polymers used according to the present invention may be obtained by polymerization and/or by extraction from plants, animals or fungi, or inflammatory tissue. The saturated fatty acid contained as an effective ingredient in the pharmaceutical composition of the present invention may be a straight chain or branched chain saturated fatty acid having about 8 carbon atoms to about 26 carbon atoms. The saturated fatty acid and water-soluble silicate polymer, effective ingredients of the present invention, can be formulated for various pharmaceutical compositions by combining with a suitable carrier or diluent for medical use. The composition of the present invention can suppress histamine release induced by a structural change in the cell membrane of the mast cell. It exhibits an excellent organism maintaining function such as cell protecting action and, therefore, is useful as a medicine such as an anti-allergic or anti-inflammatory agent.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a saturated fatty acid, and
a pharmaceutically effective amount of a water-soluble silicate polymer, wherein said water-soluble silicate polymer has a molecular weight distribution in the range of about 4,800 to about 2,000,000, as determined by gel-filtration chromatography, and has a degree of polymerization in the range of about 75 to about 33,000, and
wherein the saturated fatty acid is present in a weight ratio of from about 1:20 to about 50:1 times the amount of the water-soluble silicate polymer, calculated as silicon.

### Claim 2 (depends on 1)

A pharmaceutical composition according to claim 1 which is effective as an anti-allergy agent or as an anti-inflammatory agent.

### Claim 3 (depends on 1)

A pharmaceutical composition according to claim 1 which further comprises a saccharide crier or diluent.

### Claim 4 (depends on 1)

A pharmaceutical composition according to claim 1 wherein the saturated fatty acid comprises a straight or branched saturated fatty acid having about 8 to about 26 carbons.

### Claim 5 (depends on 1)

A pharmaceutical composition according to claim 1 which is ma form for parenteral administration selected from the group consisting of subcutaneous, intravenous, intramuscular, rectal and nasal administration, or which is in a form for oral administration selected from the group consisting of tablets, capsules, powders and liquids.

### Claim 6 (depends on 1)

A pharmaceutical composition according to claim 1 which is effective to suppress histamine release from mast cells.

### Claim 7 (depends on 1)

A pharmaceutical composition according to claim 1 wherein the degree of polymerization of said silicate polymer is in the range of about 210 to about 16,500.

### Claim 8 (depends on 1)

A pharmaceutical composition according to claim 1 which is in an injectable form comprising a solution, suspension or emulsion in an aqueous solvent or in a nonaqueous solvent.

### Claim 9

A method for enhancing the pharmacological activity of a water-soluble silicate polymer comprising mixing a pharmaceutically effective amount of a water-soluble silicate polymer with a saturated fatty acid,
wherein said water-soluble silicate polymer has a molecular weight distribution in the range of about 4,800 to about 2,000,000, as determined by gel-filtration chromatography, and has a degree of polymerization in the range of about 75 to about 33,000, and
wherein the saturated fatty acid is mixed with the water-soluble silicate polymer in a weight ratio of from about 1:20 to about 50:1 times the amount of the water-soluble silicate polymer, calculated as silicon.

### Claim 10 (depends on 9)

A method for enhancing the pharmacological activity of a water-soluble silicate polymer according to claim 9 wherein said water-soluble silicate polymer is in the form of a storage stable powder.

### Claim 11 (depends on 9)

A method for enhancing the pharmacological activity of a water-soluble silicate polymer according to claim 9 wherein the pharmacological activity enhanced is anti-allergy activity or anti-inflammatory activity.

### Claim 12 (depends on 10)

A method fin enhancing the pharmacological activity of a water-soluble silicate polymer according to claim 10 wherein said storage stable powder is obtained by providing an aqueous solution containing a water-soluble silicate polymer and a saccharide carrier or diluent, and the aqueous solution is dried to a storage stable powder.

### Claim 13 (depends on 9)

A method for enhancing the pharmacological activity of a water-soluble silicate polymer according to claim 9, wherein the saturated fatty acid comprises an aqueous solution of a fatty acid salt or an aqueous dispersion of a free fatty acid.

### Claim 14 (depends on 10)

A method for enhancing the pharmacological activity of a water-soluble silicate polymer according to claim 10, wherein the saturated fatty acid comprises an aqueous solution of a fatty acid salt or an aqueous dispersion of a free fatty acid.

### Claim 15 (depends on 9)

A method for enhancing the pharmacological activity of a water-soluble silicate polymer according to claim 9 wherein the saturated fatty acid comprises a straight chain or branched chain saturated fatty acid having about 8 carbon atoms to about 26 carbon atoms.

### Claim 16 (depends on 9)

A method for enhancing the pharmacological activity of a water-soluble silicate polymer according to claim 9 wherein the degree of polymerization of said silicate polymer is in the range of about 210 to about 16,500.

### Claim 17

A pharmaceutical composition, comprising:
a potassium or sodium salt of a saturated fatty acid, and
a pharmaceutically effective amount of a water-soluble silicate polymer, wherein said water-soluble silicate polymer has a molecular weight distribution in the range of about 4,800 to about 2,000,000, as determined by gel-filtration chromatography, and has a degree of polymerization in the range of about 75 to about 33,000, and
wherein the potassium or sodium salt of a saturated fatty acid is present in a weight ratio of from about 1:20 to about 50:1 times the amount of the water-soluble silicate polymer, calculated as silicon.

### Claim 18 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the water-soluble silicate polymer is prepared by polymerization of a silicic acid selected from the group consisting of orthosilicic acid, metasilicic acid, mesodisilicic acid, mesotrisilicic acid, and mesotetrasilicic acid.

### Claim 19 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the water-soluble silicate polymer is prepared by polymerization of a silicate selected from the group consisting of silicate sodium metasilicate anhydrous, sodium metasilicate pentahydrate, sodium sesquisilicate, sodium orthosilicate, and mixtures thereof.

### Claim 20 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the water-soluble silicate polymer is prepared from water glass.

### Claim 21 (depends on 4)

A pharmaceutical composition according to claim 4, wherein the saturated fatty acid is selected from the group consisting of caprylic acid, capric acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, heptadecanoic acid, stearic acid, icosanoic acid, heneicosanoic acid, docosanoic acid, tricosanoic acid, lignoceric acid, cerotic acid, 2-hexyldecanoic acid, 13-methylpentadecanoic acid, 16-methylheptadecanoic acid, and mixtures thereof.

### Claim 22 (depends on 4)

A pharmaceutical composition according to claim 4, wherein the saturated fatty acid is selected from the group consisting of stearic acid, 2-hexyldecanoic acid, 13-methylpentadecanoic acid, and 16-methylheptadecanoic acid.

### Claim 23 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the saturated fatty acid is water-soluble.

### Claim 24

A method for enhancing the pharmacological activity of a water-soluble silicate polymer comprising mixing a pharmaceutically effective amount of a water-soluble silicate polymer with a potassium or sodium salt of a saturated fatty acid,
wherein said water-soluble silicate polymer has a molecular weight distribution in the range of about 4,800 to about 2,000,000, as determined by gel-filtration chromatography, and has a degree of polymerization in the range of about 75 to about 33,000, and wherein the potassium or sodium salt of a saturated fatty acid is present in a weight ratio of from about 1:20 to about 50:1 times the amount of the water-soluble silicate polymer, calculated as silicon.

### Claim 25 (depends on 9)

A method according to claim 9, wherein the histamine suppression of the water-soluble silicate polymer is increased.

### Claim 26 (depends on 15)

A method according to claim 15, wherein the saturated fatty acid is selected from the group consisting of caprylic acid, capric acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, heptadecanoic acid, stearic acid, icosanoic acid, heneicosanoic acid, docosanoic acid, tricosanoic acid, lignoceric acid, cerotic acid, 2-hexyldecanoic acid, 13-methylpentadecanoic acid, 16-methylheptadecanoic acid, and mixtures thereof.

### Claim 27 (depends on 15)

A method according to claim 15, wherein the saturated fatty acid is selected from the group consisting of stearic acid, 2-hexyldecanoic acid, 13-methylpentadecanoic acid, and 16-methylheptadecanoic acid.
